Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences
Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques compos...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2018-01-01
|
| Series: | Neural Plasticity |
| Online Access: | http://dx.doi.org/10.1155/2018/5257285 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559166569316352 |
|---|---|
| author | Gloria Ortiz-Guerrero Diana Amador-Muñoz Carlos Alberto Calderón-Ospina Daniel López-Fuentes Mauricio Orlando Nava Mesa |
| author_facet | Gloria Ortiz-Guerrero Diana Amador-Muñoz Carlos Alberto Calderón-Ospina Daniel López-Fuentes Mauricio Orlando Nava Mesa |
| author_sort | Gloria Ortiz-Guerrero |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (Aβ) and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective. |
| format | Article |
| id | doaj-art-bb1d770e33974fd7a721d936fa9176d2 |
| institution | Kabale University |
| issn | 2090-5904 1687-5443 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Neural Plasticity |
| spelling | doaj-art-bb1d770e33974fd7a721d936fa9176d22025-02-03T01:30:47ZengWileyNeural Plasticity2090-59041687-54432018-01-01201810.1155/2018/52572855257285Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical ConsequencesGloria Ortiz-Guerrero0Diana Amador-Muñoz1Carlos Alberto Calderón-Ospina2Daniel López-Fuentes3Mauricio Orlando Nava Mesa4Individualized Research Learner Program, Neuromuscular Research Division, University of Kansas Medical Center, 3901 Rainbow Blvd., Kansas City, KS 66160, USANeuroscience (NEUROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 No. 63C–69, Bogotá 111221, ColombiaUnidad de Farmacología, School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 No. 63C–69, Bogotá 111221, ColombiaMedical Social Service, Hospital de San Francisco, Kra 8 No. 6A–121, Gacheta 251230, ColombiaNeuroscience (NEUROS) Research Group, School of Medicine and Health Sciences, Universidad del Rosario, Carrera 24 No. 63C–69, Bogotá 111221, ColombiaAlzheimer’s disease (AD) is the most common type of dementia, mainly encompassing cognitive decline in subjects aged ≥65 years. Further, AD is characterized by selective synaptic and neuronal degeneration, vascular dysfunction, and two histopathological features: extracellular amyloid plaques composed of amyloid beta peptide (Aβ) and neurofibrillary tangles formed by hyperphosphorylated tau protein. Dementia and AD are chronic neurodegenerative conditions with a complex physiopathology involving both genetic and environmental factors. Recent clinical studies have shown that proton pump inhibitors (PPIs) are associated with risk of dementia, including AD. However, a recent case-control study reported decreased risk of dementia. PPIs are a widely indicated class of drugs for gastric acid-related disorders, although most older adult users are not treated for the correct indication. Although neurological side effects secondary to PPIs are rare, several preclinical reports indicate that PPIs might increase Aβ levels, interact with tau protein, and affect the neuronal microenvironment through several mechanisms. Considering the controversy between PPI use and dementia risk, as well as both cognitive and neuroprotective effects, the aim of this review is to examine the relationship between PPI use and brain effects from a neurobiological and clinical perspective.http://dx.doi.org/10.1155/2018/5257285 |
| spellingShingle | Gloria Ortiz-Guerrero Diana Amador-Muñoz Carlos Alberto Calderón-Ospina Daniel López-Fuentes Mauricio Orlando Nava Mesa Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences Neural Plasticity |
| title | Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences |
| title_full | Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences |
| title_fullStr | Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences |
| title_full_unstemmed | Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences |
| title_short | Proton Pump Inhibitors and Dementia: Physiopathological Mechanisms and Clinical Consequences |
| title_sort | proton pump inhibitors and dementia physiopathological mechanisms and clinical consequences |
| url | http://dx.doi.org/10.1155/2018/5257285 |
| work_keys_str_mv | AT gloriaortizguerrero protonpumpinhibitorsanddementiaphysiopathologicalmechanismsandclinicalconsequences AT dianaamadormunoz protonpumpinhibitorsanddementiaphysiopathologicalmechanismsandclinicalconsequences AT carlosalbertocalderonospina protonpumpinhibitorsanddementiaphysiopathologicalmechanismsandclinicalconsequences AT daniellopezfuentes protonpumpinhibitorsanddementiaphysiopathologicalmechanismsandclinicalconsequences AT mauricioorlandonavamesa protonpumpinhibitorsanddementiaphysiopathologicalmechanismsandclinicalconsequences |